Researchers from UC San Diego found that a 12-month exercise intervention was associated with improvements in attention and memory among breast cancer survivors, while a companion analysis suggests exercise may also slow epigenetic aging.

The findings, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2026, suggest that an autonomous AI as a medical device (AIaMD) could help address growing pressure on dermatology services. The autonomous AI-supported pathway managed 8,391 patients, representing 94% of urgent suspected skin cancer referrals across the two hospitals.

Among cancer patients who received personalized support and navigation services from experts throughout the genetic testing process, their first-degree relatives – parents, siblings and children – were significantly more likely to receive genetic testing, as well. Nearly half of those relatives carried a BRCA1 or BRCA2 mutation, which are associated with a higher risk of cancer, according to a new study by researchers at The University of Texas MD Anderson Cancer Center.

Physicians typically use either a higher dose of cisplatin given every three weeks or a lower dose given weekly in combination with radiation to treat locally advanced head and neck cancer. However, prior to NRG-HN009, there was limited randomized evidence to determine which regimen provided the best balance of cancer control and treatment-related side effects. This question is particularly important for patients with p16-negative disease, who often have multiple comorbidities and may have a lower tolerance for intensive chemoradiation. The Phase II portion of NRG-HN009 compared these two treatment regimens in patients with p16-negative disease and found that weekly cisplatin failed to show significantly lower acute toxicity compared with cisplatin given every three weeks. Because the study did not meet its predefined criteria for reduced acute toxicity with weekly cisplatin, the p16-negative cohort did not advance to the Phase III portion of the trial.

The model incorporates key features of the tumor microenvironment, including abnormal blood vessels, elevated interstitial fluid pressure, immune cell activity, drug transport and tumor-draining lymph nodes.